Circulating MVs from the blood of patients with prostate cancer are characterized by enrichment with fragments of mutant MLH1, PTEN and TP53, whereas circulating MVs of patients with pancreatic cancer are enriched with mutant KRAS and TP53 [81]. This evidence concerns the gene TP53 and prostate carcinoma.